Multiple myeloma
Drug research and approvals for multiple myeloma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 578 studies of multiple myeloma are recruiting on ClinicalTrials.gov, Health Canada has authorized 166 drug trials for it since 2013, FDA has 48 approved and 107 open orphan designations naming it, and the EU has 36 authorised medicines for it.
- Recruiting worldwide: 578
- Trials authorized in Canada: 166
- FDA orphan approvals: 48
- EU medicines: 36
- SKCD in Early Relapsed/Refractory Multiple MyelomaNCT07931391 · Phase 2 · Beijing Chao Yang Hospital · starts Oct 31, 2026
- Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood CancersNCT07914556 · Phase 1 · Mabwell (Shanghai) Bioscience Co., Ltd. · starts Sep 16, 2026
- The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic…NCT07912684 · Not applicable · Gruppo Italiano Malattie EMatologiche dell'Adulto · starts Nov 10, 2026
- Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple MyelomaNCT07907211 · Phase 4 · Chen Lijuan · starts Feb 1, 2024
- Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple MyelomaNCT07891923 · Phase 2 · Tata Memorial Centre · starts Oct 28, 2025
- Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise)NCT07851493 · Not reported · Technical University of Munich · starts Sep 1, 2026
- SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell DisordersNCT07850284 · Not reported · Mayo Clinic · starts Aug 25, 2026
- Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants…NCT07825064 · Phase 2 · Hoffmann-La Roche · starts Nov 3, 2026
- A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or…NCT07802717 · Phase 1 · Vyriad, Inc. · starts Sep 8, 2026
Approved 24
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- Bortezomib26S proteasome inhibitor
- CyclophosphamideDNA inhibitor
- DaratumumabLymphocyte differentiation antigen CD38 inhibitor
- PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- Carfilzomib26S proteasome inhibitor
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- ElotuzumabSLAM family member 7 inhibitor
- IsatuximabLymphocyte differentiation antigen CD38 inhibitor
- Belantamab mafodotinTumor necrosis factor receptor superfamily member 17 binding agent
- DoxorubicinDNA topoisomerase II alpha inhibitor
- SelinexorExportin-1 inhibitor
- PanobinostatHistone deacetylase inhibitor
- PlerixaforC-X-C chemokine receptor type 4 partial agonist
- TeclistamabT cell surface glycoprotein CD3 binding agent
- Zoledronic acidFarnesyl diphosphate synthase inhibitor
- ElranatamabT cell surface glycoprotein CD3 binding agent
- TalquetamabT cell surface glycoprotein CD3 binding agent
- CarmustineGlutathione reductase inhibitor
- Idecabtagene vicleucelTumor necrosis factor receptor superfamily member 17 binding agent
- Melphalan flufenamideDNA cross-linking agent
- Ciltacabtagene autoleucelTumor necrosis factor receptor superfamily member 17 binding agent
- Interferon alfa-2bInterferon alpha/beta receptor agonist
- Motixafortide acetate
Phase 3 12 of 56
- DexamethasoneGlucocorticoid receptor agonist
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- PrednisoneGlucocorticoid receptor agonist
- Ixazomib26S proteasome inhibitor
- Fludarabine
- BusulfanDNA inhibitor
- BendamustineDNA inhibitor
- IberdomideCRL4(CRBN) E3 ubiquitin ligase modulator
- VorinostatHistone deacetylase 1 inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- ClarithromycinBacterial 70S ribosome inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
Phase 2 12 of 154
- TacrolimusFK506-binding protein 1A inhibitor
- Arsenic trioxideThioredoxin reductase 1 inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- MethotrexateDihydrofolate reductase inhibitor
- Ascorbic acidSupplement
- SirolimusFK506-binding protein 1A inhibitor
- TocilizumabInterleukin-6 receptor alpha subunit inhibitor
- NirogacestatGamma-secretase inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
- IbrutinibTyrosine-protein kinase BTK inhibitor
- Cevostamab
Phase 1 or earlier 12 of 189
- Oprozomib26S proteasome inhibitor
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
- IpilimumabCytotoxic T-lymphocyte protein 4 inhibitor
- Maplirpacept
- CabozantinibVascular endothelial growth factor receptor 2 inhibitor
- LGH-447Serine/threonine-protein kinase PIM inhibitor
- AtezolizumabProgrammed cell death 1 ligand 1 inhibitor
- TipifarnibProtein farnesyltransferase inhibitor
- DacetuzumabTumor necrosis factor receptor superfamily member 5 inhibitor
- Indatuximab ravtansineSyndecan-1 binding agent
- MezagitamabLymphocyte differentiation antigen CD38 binding agent
- RicolinostatHistone deacetylase 6 inhibitor
How its trials ended
3,427 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 969 whose ending is known, 35% met their primary endpoint, 4% missed it and 61% stopped early.
- Completed, result not reported1,18635%
- Ongoing95928%
- Met its primary endpoint33910%
- Status unknown3139%
- Stopped: other or unclear2718%
- Stopped: enrollment or feasibility1645%
- Stopped: sponsor or business decision852%
- Stopped: lack of efficacy431%
- Missed its primary endpoint361%
- Stopped: safety16<1%
- Stopped: funding15<1%
| Oct 20, 2026 | A phase 3, multicenter, open-label, randomized study to evaluate inobrodib in combination with pomalidomide and dexamethasone versus standard available therapy…Inobrodib (CCS1477) / Pomalidomide / Dexamethasone / Darzalex (daratumumab) /… | Cellcentric Ltd | Pending |
| Sep 25, 2026 | A randomized, open-label, phase 1b, crossover study to evaluate the pharmacokinetics and safety of a subcutaneous belantamab formulation with RHUPH20 versus…Belantamab (GSK2857914) / Recombinant human hyaluronidase PH20 (RHUPH20) | GSK | Pending |
| Jul 17, 2026 | An open label phase 1b, multicenter study to evaluate the safety and efficacy of belantamab mafodotin plus cevostamab in participants with relapsed/refractory…Belantamab mafodotin / Cevostamab | Canadian Myeloma Research Group | Pending |
| Jul 8, 2026 | A phase III, open-label, multicentre, randomised study comparing consolidation treatment with AZD0120, an autologous dual targeting chimeric antigen receptor…AZD0120 (GC012F) | AstraZeneca Pharmaceuticals | Pending |
| Jun 1, 2026 | Safety and feasibility of teclistamab discontinuation in relapsed and refractory multiple myelomaTecvayli | Ciusss De L’est-De-L’île-De-Montréal – Hôpital Maisonneuve-Rosemont | Pending |
| May 27, 2026 | A phase 3, randomized, open-label study of linvoseltamab versus daratumumab in participants with smoldering multiple myeloma at high risk of developing…Lynozyfic / Darzalex | Regeneron | Pending |
| Apr 15, 2026 | A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone…Cevostamab (RO7187797) / Imnovid / Dexamethasone / Darzalex / Empliciti /… | Roche | Ongoing |
| Apr 10, 2026 | A phase III, open-label, randomised, multicentre study of consolidation with a single administration of AZD0120, a dual-targeting autologous chimeric antigen…AZD0120 (GC012F) | AstraZeneca Pharmaceuticals | Pending |
| Apr 2, 2026 | A phase 3 randomized study comparing JNJ-79635322 versus teclistamab in participants with relapsed or refractory multiple myeloma after 1 to 3 prior lines of…JNJ-79635322 / Tecvayli | Johnson & Johnson | Ongoing |
| Mar 5, 2026 | A phase 3 randomized study comparing JNJ-79635322 and an anti-bcmaxcd3 bispecific antibody in participants with relapsed or refractory multiple myeloma who…JNJ-79635322 / Teclistamab | Johnson & Johnson | Ongoing |
| Aug 13, 2026 | ZenbexusIn combination with daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of adult patients with multiple myeloma who have… | Celgene Corporation (a Bristol-Myers Squibb Company) | Approved |
| Jul 10, 2026 | Sarclisa EscenaIn combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1… | Sanofi-Aventis U.S. LLC | Approved |
| Mar 5, 2026 | TecvayliTreatment of adult patients with relapsed or refractory multiple myeloma in combination with daratumumab hyaluronidase-fihj in patients who… | Janssen Research & Development, LLC | Approved |
| Oct 23, 2025 | BlenrepIn combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have… | GlaxoSmithKline Intellectual Property Development Ltd. | Approved |
| Jul 2, 2025 | LynozyficTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including… | Regeneron Pharmaceuticals, Inc. | Approved |
| Sep 20, 2024 | SarclisaIn combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma… | Sanofi-Aventis U.S. LLC | Approved |
| Apr 5, 2024 | CarvyktiTreatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 1 prior line of therapy, including a… | Janssen Research & Development, LLC | Approved |
| Apr 4, 2024 | AbecmaTreatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an… | Celgene Corporation, a Bristol-Myers Squibb Company | Approved |
| Sep 8, 2023 | AphexdaIn combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent… | Ayrmid Pharma Ltd. | Approved |
| Aug 14, 2023 | ElrexfioTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including… | Pfizer Inc. | Approved |
| Aug 9, 2023 | TalveyTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including… | Janssen Biotech, inc. | Approved |
| Oct 25, 2022 | TecvayliTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including… | Janssen Research & Development, LLC | Approved |
| Jun 30, 2022 | KyprolisTreatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination… | Onyx Therapeutics, Inc. | Approved |
| Feb 28, 2022 | CarvyktiTreatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome… | Janssen Research & Development, LLC | Approved |
| Nov 30, 2021 | KyprolisTreatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination… | Onyx Therapeutics, Inc. | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA